Puma Biotechnology Return On Equity vs. Price To Book
| PBYI Stock | USD 2.95 0.07 2.32% |
Return On Equity | First Reported 2010-12-31 | Previous Quarter 0.40400808 | Current Value 0.42 | Quarterly Volatility 5.83655482 |
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Gross Profit Margin | 0.88 | 0.734 |
|
|
For Puma Biotechnology profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Puma Biotechnology to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Puma Biotechnology utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Puma Biotechnology's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Puma Biotechnology over time as well as its relative position and ranking within its peers.
Puma |
Puma Biotechnology's Revenue Breakdown by Earning Segment
Check out Your Equity Center.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Puma Biotechnology. If investors know Puma will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Puma Biotechnology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 2.417 | Earnings Share 0.47 | Revenue Per Share 5.045 | Quarterly Revenue Growth 0.435 | Return On Assets 0.0973 |
The market value of Puma Biotechnology is measured differently than its book value, which is the value of Puma that is recorded on the company's balance sheet. Investors also form their own opinion of Puma Biotechnology's value that differs from its market value or its book value, called intrinsic value, which is Puma Biotechnology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Puma Biotechnology's market value can be influenced by many factors that don't directly affect Puma Biotechnology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Puma Biotechnology's value and its price as these two are different measures arrived at by different means. Investors typically determine if Puma Biotechnology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Puma Biotechnology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Puma Biotechnology Price To Book vs. Return On Equity Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Puma Biotechnology's current stock value. Our valuation model uses many indicators to compare Puma Biotechnology value to that of its competitors to determine the firm's financial worth. Puma Biotechnology is considered to be number one stock in return on equity category among its peers. It is rated below average in price to book category among its peers fabricating about 4.80 of Price To Book per Return On Equity. As of now, Puma Biotechnology's Return On Equity is increasing as compared to previous years. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Puma Biotechnology's earnings, one of the primary drivers of an investment's value.Puma Price To Book vs. Return On Equity
Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Puma Biotechnology |
| = | 0.42 |
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
Price to Book (P/B) ratio is used to relate a company book value to its current market price. A high P/B ratio indicates that investors expect executives to generate more returns on their investments from a given set of assets. Book value is the accounting value of assets minus liabilities.
Puma Biotechnology |
| = | 2.03 X |
Price to Book ratio is mostly used in financial services industries where assets and liabilities are typically represented by dollars. Although low Price to Book ratio generally implies that the firm is undervalued, it is often a good indicator that the company may be in financial or managerial distress and should be investigated more carefully.
Puma Price To Book Comparison
Puma Biotechnology is currently under evaluation in price to book category among its peers.
Puma Biotechnology Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Puma Biotechnology, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Puma Biotechnology will eventually generate negative long term returns. The profitability progress is the general direction of Puma Biotechnology's change in net profit over the period of time. It can combine multiple indicators of Puma Biotechnology, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Accumulated Other Comprehensive Income | -4 K | -4.2 K | |
| Operating Income | 32.6 M | 34.3 M | |
| Income Before Tax | 22.7 M | 23.8 M | |
| Net Income | 21.6 M | 22.7 M | |
| Net Income From Continuing Ops | 3.7 M | 3.9 M | |
| Non Operating Income Net Other | -10.5 M | -10 M | |
| Total Other Income Expense Net | -10 M | -10.5 M | |
| Net Income Applicable To Common Shares | 2.3 K | 2.4 K | |
| Income Tax Expense | 1.1 M | 1.1 M | |
| Net Interest Income | -10.8 M | -11.4 M | |
| Interest Income | 2.4 M | 1.5 M | |
| Change To Netincome | 21.7 M | 20.6 M | |
| Net Income Per Share | 0.46 | 0.48 | |
| Income Quality | 1.44 | 1.51 | |
| Net Income Per E B T | 0.95 | 0.94 |
Puma Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Puma Biotechnology. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Puma Biotechnology position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Puma Biotechnology's important profitability drivers and their relationship over time.
Use Puma Biotechnology in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Puma Biotechnology position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Puma Biotechnology will appreciate offsetting losses from the drop in the long position's value.Puma Biotechnology Pair Trading
Puma Biotechnology Pair Trading Analysis
The ability to find closely correlated positions to Puma Biotechnology could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Puma Biotechnology when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Puma Biotechnology - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Puma Biotechnology to buy it.
The correlation of Puma Biotechnology is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Puma Biotechnology moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Puma Biotechnology moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Puma Biotechnology can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Puma Biotechnology position
In addition to having Puma Biotechnology in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Macroaxis Picks Thematic Idea Now
Macroaxis Picks
Daily selected watch list of stocks of large companies handpicked by Macroaxis Team based on their diversification potential. The Macroaxis Picks theme has 50 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Macroaxis Picks Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Your Equity Center. For more detail on how to invest in Puma Stock please use our How to Invest in Puma Biotechnology guide.You can also try the Global Correlations module to find global opportunities by holding instruments from different markets.
To fully project Puma Biotechnology's future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Puma Biotechnology at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Puma Biotechnology's income statement, its balance sheet, and the statement of cash flows.